DeepMed Research

MILLENNIUM PHARMACEUTICALS, INC.

🇺🇸United States

Country: 🇺🇸United States

Ownership: Subsidiary

Established: 1993-01-01

Employees: 1K

Market Cap: -

Website: http://www.takedaoncology.com

Clinical Trials

Phase 1 Study of MLN0264 in Adult Patients With Advanced Gastrointestinal Malignancies Expressing Guanylyl Cyclase C

Phase 1

Completed

Conditions: Advanced Gastrointestinal Malignancies

Interventions: Drug: MLN0264

First Posted Date: 2012-04-16

Last Posted Date: 2016-09-07

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 41

Registration Number: NCT01577758

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Study to Investigate the Effects of Orteronel on the QT/QTc Interval in Patients With Metastatic Castration-Resistant Prostate Cancer

Phase 2

Completed

Conditions: Prostate Cancer

Interventions: Drug: Orteronel+Prednisone

First Posted Date: 2012-03-09

Last Posted Date: 2016-06-01

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 50

Registration Number: NCT01549951

Locations: 🇺🇸
Pinnacle Oncology, Scottsdale, Arizona, United States

A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas

Phase 1

Completed

Conditions: Advanced Solid Tumors
Lymphomas

Interventions: Drug: Alisertib

First Posted Date: 2012-01-19

Last Posted Date: 2019-03-15

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 36

Registration Number: NCT01512758

Locations: 🇸🇬
National Cancer Centre, Tiong Bahru, Singapore

Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma

Phase 1

Completed

Conditions: Relapsed or Refractory Anaplastic Large-cell Lymphoma
Relapsed or Refractory Hodgkin Lymphoma

Interventions: Drug: Brentuximab vedotin

First Posted Date: 2011-12-14

Last Posted Date: 2024-05-30

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 36

Registration Number: NCT01492088

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Phase 3

Completed

Conditions: Refractory Peripheral T-Cell Lymphoma
Relapsed Peripheral T-Cell Lymphoma

Interventions: Drug: Alisertib
Drug: Pralatrexate
Drug: Gemcitabine
Drug: Romidepsin

First Posted Date: 2011-12-01

Last Posted Date: 2018-07-31

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 271

Registration Number: NCT01482962

Pharmacokinetics Study of Oral IXAZOMIB in Participants With Advanced Nonhematologic Malignancies or Lymphoma

Phase 1

Completed

Conditions: Nonhematologic Malignancies
Lymphoma

Interventions: Drug: Ixazomib 4 mg Capsule A
Drug: Ixazomib 2.5 mg
Drug: Rifampin
Drug: Ixazomib 4 mg Capsule B
Drug: Ketoconazole
Drug: Clarithromycin

First Posted Date: 2011-10-18

Last Posted Date: 2017-11-01

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 112

Registration Number: NCT01454076

Dose Escalation Study of TAK-117 (MLN1117) in Subjects With Advanced Cancer

Phase 1

Completed

Conditions: Metastatic Solid Tumors

Interventions: Drug: TAK-117

First Posted Date: 2011-10-10

Last Posted Date: 2017-03-09

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 125

Registration Number: NCT01449370

Study of MLN2480 in Participants With Relapsed or Refractory Solid Tumors Followed by a Dose Expansion in Participants With Metastatic Melanoma

Phase 1

Completed

Conditions: Melanoma
Solid Tumor
Metastatic Melanoma
Neoplasm

Interventions: Drug: MLN2480

First Posted Date: 2011-08-29

Last Posted Date: 2020-08-10

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 149

Registration Number: NCT01425008

MLN8237 in Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma Treated With Rituximab +/- Vincristine

Phase 1

Completed

Conditions: Diffuse Large B-Cell Lymphoma
Transformed Follicular Lymphoma
Mantle Cell Lymphoma
Burkitt's Lymphoma

Interventions: Drug: Alisertib (MLN8237)
Drug: Rituximab
Drug: Vincristine

First Posted Date: 2011-07-20

Last Posted Date: 2018-03-27

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 45

Registration Number: NCT01397825

Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: Ixazomib
Drug: Lenalidomide
Drug: Dexamethasone

First Posted Date: 2011-06-28

Last Posted Date: 2019-03-21

Lead Sponsor: Millennium Pharmaceuticals, Inc.

Target Recruit Count: 64

Registration Number: NCT01383928

Locations: 🇺🇸
Virginia Cancer Specialists PC, Fairfax, Virginia, United States
🇺🇸
Ohio State University, Columbus, Ohio, United States
🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

and more 17 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy